Abstract/Summary:

A dose-dependent response in efficacy was observed, with analysis of covariance showing a significant lowering of sitting SBP and DBP in the 2.5 and 5 mg/day CS-3150 groups compared with placebo (all p < 0.001). CS-3150 1.25 mg/day significantly lowered sitting SBP (p = 0.0412). Target BP achievement was also dose dependent. Similarly, 24-h BP changes showed a clear dose relationship, and all CS-3150 doses significantly lowered 24-h BP compared with placebo (1.25 mg/day: p = 0.0038 and 0.0154 for 24-h SBP and DBP, respectively; 2.5 and 5 mg/day: all p < 0.0001). Compared with placebo, all CS-3150 doses were well tolerated. Hyperkalemia (>=5.5 mEq/L) was briefly detected in the 2.5 and 5 mg/day groups, but it was transient and recovered without treatment.

Authors: Ito, S.; Ito, H.; Rakugi, H; Okuda, Y; Yamakawa, S.
Keywords: Esaxerenone, non-steroidal mineralocorticoid receptor antagonist
DOI Number: 10.1097/01.hjh.0000523471.25362.f5      Publication Year: 2017

To search for other research papers by topic, keyword, author, or year, please go to our Publications page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.